Laura Korin, physician in the Hematology Service and Hematopoietic Transplantation Unit at the Alexander Fleming Institute, shared on X:
“A knockout win for glofitamab-GemOx vs R-GemOx in ASCT-ineligible R/R DLBCL!
- 4-year OS: 45.5% vs 27.1%
- CRR: 57.9% vs 23.1%
- Median DOCR: Not reached vs 18.9 months
- 3-year DOCR: 60.2% vs 48.8%
A new benchmark for future control arms.”
